Shares of Keryx Biopharmaceuticals (KERX +0.00%), a drug developer with a focus on renal disease, had an awful month: Shares were down nearly 40% in September.
What caused the huge downward move? See the presentation below for details.
Shares fell a huge 39% in September. Was there any news to justify the sell-off?
Shares of Keryx Biopharmaceuticals (KERX +0.00%), a drug developer with a focus on renal disease, had an awful month: Shares were down nearly 40% in September.
What caused the huge downward move? See the presentation below for details.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.